ClinicalTrials.gg
RecruitingNCT05936606Updated Aug 30, 2023

Tailored Anti-platelet Therapy After DES Implantation in High-risk Patients

An interventional study of Clopidogrel monotherapy and Tailored anti-platelet therapy in Coronary Artery Disease, sponsored by Yonsei University. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-08-30.

Sponsored by Yonsei University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,434
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Coronary Artery Disease by Yonsei University — 13 open to participants now, 18 under way, none of them phase 3. Coronary Artery Disease · Yonsei University.

Planned enrollment
5th of 38
3,434 · median 540
Started
2023
with 3 others
No phase
21 of 64
7 open now
Primary completion
2027-05
later than 6 of 17 live
Registered
57th of 64
by date

Among the 64 studies in Coronary Artery Disease by Yonsei University, this one is the 5th largest by planned enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2023, is one of 21 with no phase, reaches primary completion later than 6 of the 17 other live ones, and was the 57th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

13 of the 64 studies in Coronary Artery Disease by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Coronary Artery Disease by Yonsei University, or all of them as a file.
02

Study summary

Clopidogrel monotherapy has been found effective in reducing ischaemic cardiovascular and haemorrhagic complications in patients with drug-eluting stent (DES) placement. However, concerns remain about the safety of long-term clopidogrel monotherapy in high-risk patients with HPR (high platelet reactivity) who do not respond adequately to clopidogrel. This study aims to evaluate the effectiveness of a patient-tailored antiplatelet therapy strategy that considers platelet aggregation in high-risk patients with DES placement beyond 12 months after stenting.

Read the detailed description

This study will randomly assign eligible participants who underwent drug-eluting stent placement and have maintained the standard antiplatelet therapy for 12 months to either a control group or an intervention group. The control group will continue receiving clopidogrel monotherapy for 24 months regardless of their PRU (platelet reactivity unit) values. The intervention group will receive personalized antiplatelet therapy based on their PRU values: for non-HPR patients (PRU\<208), clopidogrel monotherapy will be continued; for HPR patients (PRU≥208), dual antiplatelet therapy will be prescribed based on clinical diagnosis at the time of stent implantation and individual patients' ischemic/bleeding risk profiles. Patients (≥50 years) who presented with acute myocardial infarction at the time of coronary intervention, and have high-risk characteristics (① ≥65 years ② multi-vessel disease ③ diabetes mellitus ④ chronic kidney disease ⑤ recurrent myocardial infarction) will receive ticagrelor 60 mg twice daily with aspirin, whereas the remainder will receive clopidogrel with aspirin. For high-bleeding-risk patients with two or more major bleeding risk factors according to ARC-HBR, the investigator may consider early discontinuation of dual antiplatelet therapy or de-escalation therapy like aspirin monotherapy based on the patient's risk profile. The treatment assignment ratio is 1:1. The study period will be up to 24 months from the time of randomization.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Coronary artery disease
  • antiplatelet therapy
  • platelet reactivity
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients > 18 years old
  2. Patients who previously underwent percutaneous coronary intervention with drug-eluting stent implantation 12 months (± 3 months) ago.
  3. At least one high risk characteristics of ischemic events

High risk patients

  1. Acute coronary syndrome
  2. Previous history of cerebrovascular accidents
  3. Previous history of peripheral artery intervention
  4. Heart failure
  5. Diabetes mellitus requiring medication
  6. Chronic kidney disease (regardless of requirement of renal replacement therapy)

High risk lesions

  1. Left main disease
  2. Multivessel disease, 2- or 3- vessels
  3. Bifurcation lesions requiring 2 or more stents
  4. Chronic total occlusion
  5. In-stent restenosis
  6. Graft lesions
  7. Diffuse long lesion requiring stent(s) with total stent length ≥28 mm
  8. Lesion at small sized vessel requiring stent(s) with stent diameter ≤2.5 mm
  9. Calcified lesions requiring atherectomy

Exclusion criteria

Exclusion Criteria:

  1. Patients > 80 years old
  2. Pregnant women or women with potential childbearing
  3. \< 1 year
  4. Refusal or inability to understand of
  5. Patients eligible to long-term anticoagulation therapy
  6. Patients with major bleeding events in previous 3 months before randomization
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,434 participants (estimated)

Study arms

  • Active comparator
    Uniform Therapy

    Patients will continue clopidogrel monotherapy for 24 months from randomization, irrespective of their PRU measurement.

    Drug: Clopidogrel monotherapy

  • Experimental
    Tailored Therapy

    Patients in the intervention arm will receive tailored anti-platelet therapy according to PRU and bleeding risk

    Drug: Tailored anti-platelet therapy

Interventions

  • DrugClopidogrelStudies of ClopidogrelClopidogrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive clopidogrel monotherapy (75 mg qd) for 24 months after randomization, irrespective of PRU value or bleeding risk.

  • DrugTailored anti-platelet therapy

    In the tailored therapy arm, non-HPR (PRU\<208) patients will continue clopidogrel monotherapy until the end of the study at 24 months from randomization, while HPR (PRU≥208) patients will receive dual anti-platelet therapy according to the clinical diagnosis at the time of drug-eluting stent placement: High-risk patients with prior myocardial infarction will receive ticagrelor 60 mg twice daily wiht aspirin 100 mg daily, while the remainder will receive clopidogrel 75 mg daily with aspirin 100 mg daily. For HBR patietns, early cessation of dual antiplatelet therapy or aspirin monotherapy could be considered at the investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Net Clinical Adverse Clinical Events (NACE) for 24 months

    A composite of all-cause of death, myocardial infarction (MI), stent thrombosis, stroke, or BARC type 2, 3, or 5 bleeding

    Time frame: upto 2 years after randomization

Secondary outcomes

  1. All-cause death

    Time frame: upto 2 years after randomization

  2. Cardiovascular death

    Time frame: upto 2 years after randomization

  3. Myocardial infarction

    Time frame: upto 2 years after randomization

  4. Stent thrombosis

    Time frame: upto 2 years after randomization

  5. Ischemia-driven target vessel revascularization

    Time frame: upto 2 years after randomization

  6. Any revascularization

    Time frame: upto 2 years after randomization

  7. Stroke

    Time frame: upto 2 years after randomization

  8. Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding

    Time frame: upto 2 years after randomization

  9. Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding

    Time frame: upto 2 years after randomization

  10. Bleeding Academic Research Consortium (BARC) type 2 bleeding

    Time frame: upto 2 years after randomization

  11. Bleeding Academic Research Consortium (BARC) type 3 bleeding

    Time frame: upto 2 years after randomization

  12. Bleeding Academic Research Consortium (BARC) type 5 bleeding

    Time frame: upto 2 years after randomization

  13. All-cause death, myocardial infarction, or stroke

    Time frame: upto 2 years after randomization

  14. Cardiovascular death, myocardial infarction, stent thrombosis, or stroke

    Time frame: upto 2 years after randomization

  15. All-cause death, myocardial infarction, stent thrombosis, stroke, or BARC type 3 or 5 bleeding

    Time frame: upto 2 years after randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for May 2027, 45 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 45 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2023
First posted
Jul 10, 2023
StartActual
Aug 16, 2023
Primary completionEst.
May 2027
CompletionEst.
May 2029
Last update
Aug 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05936606
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Jul 10, 2023
Start date
Aug 16, 2023
Primary completion
May 2027 (estimated)
Completion
May 2029 (estimated)
Last update
Aug 30, 2023

Study contacts

Byeong-Keuk Kim
Contact
kimbk@yuhs.ac
02-2228-8465
Byeong-Keuk Kim
principal investigator · Severance Cardiovascular Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion